Status:
COMPLETED
A Study of Multiple Doses of LY3305677 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
20-65 years
Phase:
PHASE1
Brief Summary
The purposes of this study are to determine: * The safety of LY3305677 and any side effects that might be associated with it. * How much LY3305677 gets into the bloodstream and how long it takes the ...
Eligibility Criteria
Inclusion
- Are overtly healthy males or females, as determined by medical history and physical examination
- Women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause
- Are first-generation Japanese or non-Japanese. First-generation Japanese is defined as the participant, the participant's biological parents, and all of the participant's grandparents are of exclusive Japanese descent and have been born in Japan
- Have a body weight of more than 54 kilograms (kg)
Exclusion
- Currently enrolled in a clinical study or have participated in a study within the past 3 months
- Have an abnormality in the 12-lead electrocardiogram (ECG) at screening
- Have history of pancreatitis
- Have known or ongoing psychiatric disorders
- Have undergone bariatric surgery or have used any drugs for weight loss
- Have a history of alcoholism
- Currently smoke more than 10 cigarettes a day
Key Trial Info
Start Date :
October 27 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2018
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03325387
Start Date
October 27 2017
End Date
August 3 2018
Last Update
August 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Leeds, West Yorkshire, United Kingdom, LS2 9LH